Thumbnail Image
Item

Health-related quality-of-life results from the phase 3 OPTIMISMM study: pomalidomide, bortezomib, and low-dose dexamethasone versus bortezomib and low-dose dexamethasone in relapsed or refractory multiple myeloma

Weisel, Katja
; 
Dimopoulos, Meletios
; 
Moreau, Philippe
; 
Yagci, Munci
; 
Larocca, Alessandra
; 
Kanate, Abraham S
; 
Vural, Filiz
; 
Cascavilla, Nicola
; 
Basu, Supratik
; 
Johnson, Peter
... show 10 more
Authors
Weisel, Katja
 Dimopoulos, Meletios
 Moreau, Philippe
 Yagci, Munci
 Larocca, Alessandra
 Kanate, Abraham S
 Vural, Filiz
 Cascavilla, Nicola
 Basu, Supratik
 Johnson, Peter
 Byeff, Peter
 Hus, Marek
 Rodriguez-Otero, Paula
 Muelduer, Ercan
 Antilla, Pekka
 Hayden, Patrick J
 Krauth, Maria-Theresa
 Lucio, Paulo
 Ben-Yehuda, Dina
 Mendeleeva, Larisa
 Guo, Shien
 Yu, Xin
 Grote, Lara
 Biyukov, Tsvetan
 Dhanasiri, Sujith
 Richardson, Paul
Editors
Other contributors
Affiliation
Epub Date
Issue Date
2020-01-01
Submitted date
Subjects
HRQoL
 quality of life
 bortezomib
 dexamethasone
 multiple myeloma
 pomalidomide
Show all metadata
Files
Thumbnail Image
Basu_Health_Related_Quality_2020.pdf
Adobe PDF, 1.1 MB
Alternative
Abstract
In the randomized phase-3 OPTIMISMM study, the addition of pomalidomide to bortezomib and low-dose dexamethasone (PVd) resulted in significant improvement in progression-free survival (PFS) in lenalidomide-pretreated patients with relapsed or refractory multiple myeloma (RRMM), including lenalidomide refractory patients. Here, we report health-related quality of life (HRQoL) results from this trial. Patients received PVd or Vd in 21-day cycles until disease progression or discontinuation. HRQoL was assessed using the EORTC QLQ-C30, QLQ-MY20, and EQ-5D-3L instruments on day 1 of each treatment cycle. Mean score changes for global QoL, physical functioning, fatigue, side effects of treatment domains, and EQ-5D-3L index were generally stable over time across treatment arms. The proportion of patients who experienced clinically meaningful worsening in global QoL and other domains of interest was similar. These HRQoL results with PVd along with previously demonstrated improvement in PFS vs Vd continue to support its use in patients with RRMM.
Citation
Weisel, K., Dimopoulos, M., Moreau, P. and Yagci, M. (2020) Health-related quality-of-life results from the phase 3 OPTIMISMM study: pomalidomide, bortezomib, and low-dose dexamethasone versus bortezomib and low-dose dexamethasone in relapsed or refractory multiple myeloma, Leukemia & Lymphoma, 61 (8), pp. 1850-1859, DOI: 10.1080/10428194.2020.1747066
Publisher
Informa UK Limited
Journal
Leukemia and Lymphoma
Research Unit
URI
http://hdl.handle.net/2436/623533
DOI
10.1080/10428194.2020.1747066
PubMed ID
32268815 (pubmed)
PubMed Central ID
Embedded videos
Additional Links
https://www.tandfonline.com/doi/full/10.1080/10428194.2020.1747066
Type
Journal article
Language
en
Description
This is an accepted manuscript of an article published by Taylor & Francis in Leukemia & Lymphoma on 09/04/2020, available online: https://www.tandfonline.com/doi/full/10.1080/10428194.2020.1747066 The accepted version of the publication may differ from the final published version.
Series/Report no.
ISSN
1042-8194
EISSN
1029-2403
ISBN
ISMN
Gov't Doc #
Sponsors
This work was supported by Celgene Corporation.
Rights
Research Projects
Organizational Units
Journal Issue
Embedded videos
Collections
Faculty of Science and Engineering